Cardiovascular Journal of Africa: Vol 28 No 4 (July/August 2017)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 4, July/August 2017

AFRICA

247

31. World Health Organisation. Guidelines for Medicine Donations.

Revised 2010. Geneva, Switzerland.

32. Wyber R, Taubert K, Marko S, Kaplan EL. Benzathine penicillin G

for the management of RHD: Concerns about quality and access, and

opportunities for intervention and improvement. Glob.

Heart

2013;

227–234.

33. International Rheumatic Fever Study Group. Allergic reactions to long-

term benzathine penicillin prophylaxis for rheumatic fever.

Lancet

1991;

337

: 1308–1310.

34. Kaya A, Erkoço

lu M, Senkon OG,

et al.

Confirmed penicillin allergy

among patients receiving benzathine penicillin prophylaxis for acute

rheumatic fever.

Allergol Immunopathol (Madr)

;

: 289–292.

35. World Health Organisation Pharmaceuticals Newsletter, 2000;

36. Global status of BPG report. RHD Action.

http://rhdaction.org/

sites/default/files/RHD Action_Global Status of BPG Report_Online

Version.pdf (accessed Aug 22, 2016).

Confidence Through Clinical and Real World Experience

1-3

Millions of Patients Treated Worldwide Across Multiple Indications

#1 Scripted Non-VKA Oral Anticoagulant by Cardiologists*

*Impact RX Data 2016

NOAC: Non Vitamin K Oral Anticoagulant

REFERENCES:

1. Patel M.R., Mahaffey K.W., Garg J.

et al

. Rivaroxaban versus warfarin in non-valvular atrial fi brillation.

N Engl J Med

. 2011;365(10):883–91. 2. Tamayo S., Peacock W.F., Patel M.R.,

et al

. Characterizing

major bleeding in patients with nonvalvular atrial fi brillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.

Clin Cardiol

. 2015;38(2):63–8. 3. Camm A.J., Amarenco P., Haas S.

et al

. XANTUS: A

Real-World, Prospective, Observational Study. 4. Calculation based on IMS Health MIDAS, Database: Monthly Sales January 2017.

S4 Xarelto 15: Each film-coated tablet contains rivaroxaban 15 mg. Reg. No: 46/8.2/0111; Namibia NS2 : 12/8.2/0006; S2 Botswana: BOT1302296; Zimbabwe: PP10 Reg. 2017/10.2/5363

S4 Xarelto 20: Each film-coated tablet contains rivaroxaban 20 mg. Reg. No: 46/8.2/0112;Namibia NS2 : 12/8.2/0007; S2 Botswana: BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364

PHARMACOLOGICAL CLASSIFICATION:

A.8.2 Anticoagulants.

INDICATIONS:

(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2) Treatment of deep vein thrombosis

(DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep

vein thrombosis (DVT). For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority (MCC).

HCR:

Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando,

1609. Tel: 011 921 5044 Fax: 011 921 5041.

L.ZA.MKT.GM

06.2017.1808